Intrivo has introduced a new rapid Covid-19 antigen test, On/Go One, which can detect all major known variants, including Omicron.
The antigen test recently secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA).
The new affordable and portable Covid-19 test provides 98.2% accurate results in 15 minutes and fits in the palm of the hand.
It is paired with the On/Go companion mobile application, which includes live non-medical support, virtual health resources, instructional videos and testing guidance.
Individuals with or without symptoms can use the test, which has a 12-month shelf life.
Intrivo co-CEO Ron Gutman said: “On/Go One represents the next frontier in Intrivo’s mission to help all Americans everywhere live happier, healthier, safer lives by helping to detect and control current and future variants, and finally making the pandemic endemic once and for all.
“Our all-new On/Go One test is potent enough to detect Covid-19 with a single, rapid test (unlike competitive products that typically require two tests), and was developed and FDA-authorised with our top-rated On/Go companion app and underlying technology, enabling ease of use for consumers and real-time data and insights for population health managers and governments.
“Together, we can now detect the emergence and spread of a potential new outbreak when it starts to emerge, before it’s too late to respond locally and avoid the consequences we’ve experienced in past waves.”
The company stated that users will be directed to an Advanced Care Toolkit (ACT) if they test positive.
The ACT includes access to a specifically trained Care Guides team, which will provide non-medical support as well as guidance regarding next steps.
Furthermore, On/Go has collaborated with Optum to provide immediate access to same-day virtual appointments with a trained medical provider for assistance.
Last October, Intrivo launched On/Go, a new at-home rapid Covid-19 antigen self-test.